Arbutus Biopharma Corporation - Common Stock — Flux de trésorerie trimestriel (NASDAQ:ABUS)

Afficher le graphique complet Full chart

Financials

Total de l'actif 131.71 M117.01 M103.27 M97.71 M94.62 M277.16 M Total du passif 34.34 M37.85 M20.29 M20.31 M18.04 M16.99 M Total des capitaux propres 97.37 M79.16 M82.98 M77.4 M76.58 M260.18 M Total du passif et des capitaux propres 131.71 M117.01 M103.27 M97.71 M94.62 M277.16 M Dette totale —————— Dette nette ——————

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation - Common Stock

Nouvelles

Le BPA de Arbutus Biopharma a dépassé les attentes de 0,91$, le CA a surpassé les prévisions

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)

Moderna's Revenues See Strong International Momentum in Q1 Earnings

L'Europe approuve le premier vaccin combiné contre la grippe/COVID de Moderna | Benzinga France

Moderna's Quarterly Earnings Preview: What You Need to Know

Le BPA de Arbutus Biopharma a dépassé les attentes de 0,02$, le CA a surpassé les prévisions

Moderna conclut un accord de 950 millions de dollars avec Arbutus et Genevant

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Chardan réitère sa recommandation sur l’action Arbutus Biopharma après l’accord avec Moderna

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS